GAVI'S CONTINUED ROLE IN YELLOW FEVER CONTROL

BOARD MEETING

Michael F Thomas

7-8 December 2016, Abidjan, Côte d'Ivoire



EVOLVING CONTEXT: THREATS AND OPPORTUNITIES

Yellow fever is a global threat

- Endemic in 47 countries (30 Gavi eligible) worldwide with recent outbreaks
- International and intra-national transmission has occurred
- Potential for further expansion due to urbanisation, large population movements, climate change

Gavi's investment to date has had a favorable impact on Yellow Fever in Africa

- From 2000 over \$300M invested and over 200m immunised through 2015
- Support has been aligned with global initiatives but largely reactive to needs



Board Meeting 7-8 December 2016

Opportunities for improved coverage in 2017-2020

- Three-pronged vaccination strategy
- Vaccine supply
- Accountability and coordination



LESSONS LEARNED FROM PREVIOUS YELLOW FEVER INITIATIVES

The three-pronged vaccination strategy is effective when properly implemented

Routine immunisation, mass preventive campaigns and emergency stockpile

Recent supply constraints have resulted in sub-optimal implementation of effective YF control strategies

- Partial implementation of mass preventive campaigns in Ghana, Nigeria and Sudan
- Outbreaks in Angola and DR Congo


Global processes need to be strengthened to meet the challenges of controlling Yellow Fever

• Governance, accountability and advocacy are required to ensure better country engagement and implementation of recommended strategies



VACCINE SUPPLY LANDSCAPE EXPECTED TO IMPROVE

- Alliance efforts have resulted in a commitment to improved YF vaccine production after several years of insufficient supply
- Production anticipated to increase from 72m doses annually in 2015 to ~140m doses by 2020
- Dynamic nature of supply and estimated country needs requires close coordination
- Gavi increment volumes requested are a subset of EYE global demand





ELIMINATING YELLOW FEVER (EYE) OUTBREAKS STRATEGY, 2016-2026

Global in scope

• 47 endemic countries

Active Gavi engagement with WHO in development stages

Strategic objectives

- Protect at risk populations
- Prevent international spread
- Rapidly contain outbreaks

New elements

- Risk classification
- Revolving stockpile
- Catch-up campaigns
- Strengthened governance and accountability
- International Health Regulation (IHR)



GAVI'S APPROACH TO SUPPORT THE IMPLEMENTATION OF THE STRATEGY

- Work with WHO and stakeholders to strengthen oversight, governance and accountability
- Investment centred on improving sustainable immunisation in alignment with Coverage and Equity agenda
- Continue to work with manufacturers to realise supply increases through 2021



ESTIMATED GAVI SUPPORT INCREASES BY \$150 MILLION

Existing estimates

U\$278m

Dec-15 Board 2016-2020



- Ongoing support for YF RI in 15 countries
- Partial supply of YF RI in 4 new countries from 2019 or earlier
- Partial supply for SIAs in 3 countries
- Support for emergency stockpile

Estimated increment

US\$150m



- Install 4 new RI programmes
 - Supplemental doses for 3 approved SIAs; additional country SIA
- Increased support for revolving stockpile

Total estimates | US\$ 428 million and 260 million doses



RECOMMENDATION

The Gavi Alliance Programme and Policy Committee recommended to the Gavi Alliance Board that it:

- a) <u>Agree</u> that Gavi's support for Yellow Fever vaccine be based on the Eliminating Yellow Fever Epidemics Strategy developed by WHO (the "EYE Strategy").
- b) <u>Note</u> that due to increased supply availability and the identified need to improve Yellow Fever vaccine coverage in endemic countries to introduce, forecasted expenditure on Yellow Fever vaccine support in Gavi eligible countries in the period 2017-2020 will increase by approximately up to US\$ 150 million.



Thank you



